Review of economic data on closed system transfer drug for preparation and administration of hazardous drugs

Annaelle Soubieux,1 Cynthia Tanguay,1 Jean Lachaine,2 Jean-François Bussières1,2

ABSTRACT
Objectives The objectives of this study were to review economic data on the use of closed system drug transfer devices (CSTDs) for preparing and administering hazardous drugs, and to evaluate the quality of data reporting as defined by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).
Methods All references from a recent Cochrane review about CSTDs were evaluated for inclusion. A literature review was also conducted. Articles containing economic data about the use of CSTDs were retained for analysis. Two researchers independently graded the articles according to the 24-item CHEERS checklist.
Results Of the 138 articles identified initially, 12 were retained for analysis. Nine of these studies did not report acquisition costs or did not detail acquisition costs. Six studies reported economic benefits associated with the use of CSTDs, all related to extending the beyond-use date. The mean number of CHEERS criteria fulfilled by the included articles was 9.2 (SD 2.4).
Conclusions CSTDs are costly to acquire. However, few studies have examined the economic impact of these devices, and the existing studies are incomplete. As a result, hospitals planning to implement these devices will be unable to make a sound economic evaluation. Robust economic evaluation of CSTDs is needed.

INTRODUCTION
Hazardous drugs are compounds that are carcinogenic or teratogenic, or that present reproductive, organ or genetic toxicity.1 Healthcare workers, especially nurses and pharmacy personnel, experience occupational exposure to these hazardous drugs. Various strategies are used to limit surface contamination and workers’ exposure, such as using biological safety cabinets, priming intravenous tubing in the pharmacy, using personnel protective devices, and providing training.1

Closed system drug transfer devices (CSTDs) can be used for preparing and administering hazardous drugs, in conjunction with other safe handling techniques. These devices create a ‘closed’ environment that prevents aerosols from escaping.3 Although CSTDs provide additional protection, they must be used inside a safety cabinet for the preparation of hazardous drugs.6

A recent Cochrane review concluded that there is no high-quality evidence to support (or refute) the routine use of these devices in addition to safe handling.3 Even though some studies have shown a reduction in contamination with use of CSTDs,4,5 others have reported lower surface contamination without their use.6 Some of these CSTD studies had observation biases and lacked an adequate control group. Many groups have shown a reduction in surface contamination over time, without using CSTDs.7,8 Certain technical flaws have also been reported (eg, spills, trouble handling the devices).9–11

A key impediment to use of CSTDs is their high cost.12 One hospital estimated a yearly cost of US$1.5 million to implement CSTDs.12 Another centre stopped its participation in a study because of the high acquisition costs.13 Yet another centre reported spending 75% more in implementation costs than what had been estimated by the vendor.14 To make an informed decision about CSTDs, healthcare organisations must be able to adequately evaluate the costs involved, especially considering the uncertainty regarding the health benefits for workers.

To date, economic evaluations on the use of CSTDs appear to be incomplete.3 The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) can be used to design and evaluate economic data in healthcare settings to ensure adequate reporting of all key variables.15

The objectives of this study were to review economic data on the use of CSTDs for preparing and administering hazardous drugs and to evaluate the quality of data reporting as defined by the CHEERS criteria.13

METHODS
Study selection All references from the Cochrane study were considered for inclusion. In addition, a literature review was conducted on 12 March 2018 using the PubMed, CINAHL, HAL, ERUDIT and thes. fr databases, a cost-effectiveness analysis registry16 and the Economic Evaluation Database of the National Health Service (UK).17 The following search terms were used: ‘closed system transfer device’ OR ‘CSTD’. A manual search was also conducted.

For articles selected on the basis of initial screening of titles, the full text was read to identify articles relevant for this review. All studies that presented economic data on the use of CSTDs were included, even if economic evaluation was not their main goal. A spreadsheet with the following elements was created: author, year and country of each study, the CSTD evaluated; costs and cost savings; and study limitations.
Quality of reporting
For all included studies, the CHEERS checklist was applied (n=24 criteria). For each study, every criterion was reviewed (and categorised as yes, no or not applicable) independently by two members of the research team (AS, CT). Differences were resolved by consensus.

RESULTS
Economic data on the use of CSTDs
A total of 12 studies were included (figure 1): 10 original articles, one thesis and one poster presentation. Studies were conducted in six countries: USA (n=4), Spain (n=3), France (n=2), Malaysia (n=1), Hungary (n=1) and Turkey (n=1). All but one of the studies took place in a hospital setting; the single exception was conducted in a veterinary setting. The PhaSeal device (Becton Dickinson) was the CSTD most frequently evaluated (in nine of the 12 studies).

Six of the studies presented economic data about preparing and administering hazardous drugs, four examined the costs and estimated costs (table 1). For each study, every criterion was reviewed (and categorised as yes, no or not applicable) independently by two members of the research team (AS, CT). Differences were resolved by consensus.

Two studies presented actual costs (table 1), six showed estimated costs (table 2), and four used a combination of actual and estimated costs (table 3). Five studies concluded that there were cost savings associated with using CSTDs, whereas seven showed that costs increased. Among the five studies that reported cost savings, two did not calculate the acquisition costs. Notably, acquisition cost was the direct cost that was most frequently evaluated (n=10). However, seven of these studies did not provide detailed itemisation of costs. Other direct costs included workers’ time (n=2) and drug costs (n=5). One study evaluated the additional waste generated by the CSTDs and another evaluated the cost of drugs lost in the ‘dead space’ of these devices. Of the eight studies evaluating the costs, four did not detail costs per dose prepared (CSTDs or conventional system). Six studies evaluated cost savings in terms of being able to extend the beyond-use date beyond that specified by US Pharmacopoeia standards (from 6 hours to 7 days), hypothesising that the CSTD could prolong sterility up to 7 days.

Quality of reporting
Two studies were excluded from the CHEERS analysis: the poster presentation, which lacked detailed results, and one study that contained only a brief mention of costs and no formal economic evaluation. Among the remaining 10 studies, the mean number of CHEERS criteria fulfilled was 9.2 (SD 2.4) out of 24. The maximum number of criteria observed in a single study was 12. In most studies, key elements were lacking, notably an abstract with structured economic data, a control group (or details about selection of controls), the study perspective, the choice of outcome measures and their efficacy, an uncertainty analysis, and sources of funding (figure 2). None of the studies included a sensitivity analysis. In only four studies did the authors declare no conflicts of interest; five others declared conflicts of interests related to the manufacturers, and three studies failed to mention potential conflicts.

DISCUSSION
CSTD costs
Only 12 studies that presented results on costs associated with the use of CSTDs were found, and all were of low quality. This dearth of data is unfortunate, considering the high costs of these devices. In addition, no study presented a thorough economic evaluation that met most or all of the CHEERS criteria, and key results were lacking from all of the studies.

Only one study took into account actual acquisition costs. Actual acquisition costs ranged between $15.73 and $24.09 per dose. However, costs were not detailed, and acquisition costs were often the only costs used. In four of the eight studies evaluating the costs, the costs per dose were not detailed. The number of preparations varied from one hospital to another, so per cost per dose is probably the most relevant outcome for readers to position themselves on.

Table 1 Economic data on closed system drug transfer devices from studies that reported actual costs

<table>
<thead>
<tr>
<th>Reference</th>
<th>CSTD</th>
<th>Costs</th>
<th>Cost savings</th>
<th>CHEERS criteria</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
<td>CSTD</td>
<td>Costs</td>
<td>Cost savings</td>
<td>CHEERS criteria</td>
<td>Limitations</td>
</tr>
<tr>
<td>Ozyaman (2016) Turkey</td>
<td>PhaSeal</td>
<td>Not evaluated</td>
<td>Extension of BUD</td>
<td>€36 137/3 months</td>
<td>NA</td>
</tr>
<tr>
<td>Kicenuik et al (2017) USA</td>
<td>Equashield</td>
<td>Acquisition costs, administration time</td>
<td>Not evaluated</td>
<td>Not evaluated</td>
<td>12/24</td>
</tr>
</tbody>
</table>

* BUD, beyond-use date; CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CSTD, closed system transfer device; NA, not applicable.
<table>
<thead>
<tr>
<th>Reference</th>
<th>CSTD</th>
<th>Costs</th>
<th>Costs saving</th>
<th>CHEERS criteria</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Massoomi et al (2008) USA&lt;sup&gt;10&lt;/sup&gt;</td>
<td>PhaSeal</td>
<td>Estimated costs</td>
<td>Not evaluated</td>
<td>NA</td>
<td>Costs not detailed. No control group. Conflicts of interest not specified.</td>
</tr>
<tr>
<td>Mullot et al (2008) France&lt;sup&gt;10&lt;/sup&gt;</td>
<td>Tevadaptor Phaseal</td>
<td>Estimated costs: acquisition costs, sterilisation costs, volume of waste, preparation time</td>
<td>Not evaluated</td>
<td>8/24</td>
<td>Costs and costs per dose not detailed. No control group without CSTD.</td>
</tr>
<tr>
<td>Rowe et al (2012) USA&lt;sup&gt;11&lt;/sup&gt;</td>
<td>PhaSeal</td>
<td>Not evaluated</td>
<td>Not evaluated</td>
<td>10/24</td>
<td>Costs not detailed. Theoretical reported savings. No control group. Conflict of interest: Carmel Pharma</td>
</tr>
<tr>
<td>Juhasz (2016) Hungary&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tevadaptor (compared with conventional system)</td>
<td>Not evaluated</td>
<td>Not evaluated</td>
<td>13/24</td>
<td>Acquisition costs not evaluated.</td>
</tr>
<tr>
<td>Forte Pérez-Minayo et al (2016) Spain&lt;sup&gt;11&lt;/sup&gt;</td>
<td>SmartSite Vented Phial Access Device SmartSite VialShield Closed Access Device</td>
<td>Estimated costs</td>
<td>Not evaluated</td>
<td>6/24</td>
<td>Costs and costs per dose not detailed. Use of a single component of the CSTD (awl)*. No comparison with a conventional system.</td>
</tr>
<tr>
<td>Caladó-Gómez et al (2017) Spain&lt;sup&gt;13&lt;/sup&gt;</td>
<td>Phaseal, SmartSite, Carefusion VM04, Hospira Clave CH70, Hospira Clave CH74, Fresenius Extraspike, Chemo V Minispike, ChemoAide</td>
<td>Estimated acquisition costs, drug loss</td>
<td>Not evaluated</td>
<td>12/24</td>
<td>No control group without CSTD. Conflicts of interest not specified.</td>
</tr>
</tbody>
</table>

*Bud perforator
BUD, beyond-use-date; CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CSTD, closed system transfer device; NA, not applicable.
the economic impact of CSTDs in their hospital. Economic evaluations on the use of CSTDs should also consider storage, elimination of waste, implementation and training time, and the quantity of drugs lost in the devices.

**COST SAVINGS**

There was marked inconsistency in the conclusions: some studies presented high costs, and others reported important cost savings. The savings were based mainly on extending the beyond-use date. The US Pharmacopoeia requires a preparation to be used within 6 hours. Some authors claim that using a CSTD can preserve the sterility and that preparations can be kept for up to 7 days. Studies supporting this claim have methodological flaws and lack all costs (and cost savings) to allow generalisation and reproducibility. Sensitivity analyses should also be conducted. Authors of future studies are encouraged to review the CHEERS checklist to improve the quality of the results reported; the criteria should also be reviewed when designing the study. In addition to comparing several CSTDs, authors should make sure to include the costs of the conventional system for preparing and administering hazardous drugs and determine the quantity of devices needed per dose and overall. None of the included studies involved a formal economic evaluation. Such a study should also be free from any conflict of interest. Ideally, economic studies should also include efficacy criteria. Although the US Pharmacopoeia recommends use of CSTDs for the administration of hazardous drugs, this organisation also emphasises that there is no guarantee that all CSTDs will perform adequately. A performance protocol for CSTDs is needed, in addition to well conducted studies designed to evaluate if their use can lead to measurable health benefits for workers.

A centre looking to implement CSTDs should critically review the literature to support their choice. It should first include an evaluation of their current working practices to identify other safe handling practices that could be applied. It is recommended that environmental monitoring is performed twice per year to identify the current state of surface contamination; it would be ideal to have at least 1 year of data before implementing a change to avoid confusing the effect of an increase in workers’ awareness with the effect of the change implemented. Centres should make sure that

**Quality of reporting**

The majority of the CHEERS criteria were not reported. In the included studies, the reported methods for calculating costs lacked details, and cost data were incomplete. Future studies should detail all costs (and cost savings) to allow generalisation and reproducibility. Sensitivity analyses should also be conducted. Authors of future studies are encouraged to review the CHEERS checklist to improve the quality of the results reported; the criteria should also be reviewed when designing the study. In addition to comparing several CSTDs, authors should make sure to include the costs of the conventional system for preparing and administering hazardous drugs and determine the quantity of devices needed per dose and overall. None of the included studies involved a formal economic evaluation. Such a study should also be free from any conflict of interest. Ideally, economic studies should also include efficacy criteria. Although the US Pharmacopoeia recommends use of CSTDs for the administration of hazardous drugs, this organisation also emphasises that there is no guarantee that all CSTDs will perform adequately. A performance protocol for CSTDs is needed, in addition to well conducted studies designed to evaluate if their use can lead to measurable health benefits for workers.

A centre looking to implement CSTDs should critically review the literature to support their choice. It should first include an evaluation of their current working practices to identify other safe handling practices that could be applied. It is recommended that environmental monitoring is performed twice per year to identify the current state of surface contamination; it would be ideal to have at least 1 year of data before implementing a change to avoid confusing the effect of an increase in workers’ awareness with the effect of the change implemented. Centres should make sure that

**Table 3** Economic data on closed system drug transfer devices from studies that reported both actual and estimated costs

<table>
<thead>
<tr>
<th>Reference</th>
<th>CSTD Type</th>
<th>Costs Type</th>
<th>Values</th>
<th>Costs saving Type</th>
<th>Values</th>
<th>CHEERS criteria</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barny et al 2015 France</td>
<td>Phaseal (compared with conventional system)</td>
<td>Acquisition costs, preparation time, ganciclovir costs</td>
<td>Phaseal: €39.04±37.26/preparation</td>
<td>Conventional system: €34.19±11.39/preparation</td>
<td>Estimated savings by extension of BUD Estimated savings if not all parts of the system are used</td>
<td>10/24</td>
<td>Costs not detailed. Conflict of interest: thanks to Becton Dickinson.</td>
</tr>
<tr>
<td>González-Haba et al 2016 Spain</td>
<td>ChemoClave (eight combinations tested)</td>
<td>Acquisition costs, preparation time, estimated annual cost</td>
<td>Between €4.46 and €8.52/dose, between 41.0 and 77.0 s/dose</td>
<td>Estimated savings of BUD Estimated savings if not all parts of the system are used</td>
<td>6/24</td>
<td>Acquisition cost not detailed. No control group without CSTD. Simulated preparations. Conflicts of interest not specified.</td>
<td></td>
</tr>
<tr>
<td>Chan et al 2016 Malaysia</td>
<td>Phaseal (compared with conventional system)</td>
<td>Acquisition costs (CSTD +other consumables), drug costs, estimated cost per dose, estimated annual cost, estimated costs for conventional system.</td>
<td>Phaseal: US$920.072/3 months US$231.06/3 months (acquisition costs only) US$40.92/prepare ganciclovir US$368.2/289/year Conventional system: US$831.5/3 months US$988.03/3 months (acquisition costs only)</td>
<td>Extension of BUD</td>
<td>10.5% of drug costs</td>
<td>11/24</td>
<td>Costs per dose for conventional system not detailed. Conflict of interest: Becton Dickinson provided information.</td>
</tr>
</tbody>
</table>

BUD, beyond-use date; CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CSTD, closed system transfer device.

**Conflict of interest:**

Simulated preparations.

Conflict of interest: thanks to Becton Dickinson.

Conflict of interest: Seattle Genetics.

Conflict of interest: Millennium and Seattle Genetics.

Conflict of interest: Becton Dickinson provided information.

Conflict of interest: Becton Dickinson.

Conflict of interest: Seattle Genetics.

Conflict of interest: Becton Dickinson.
they consider all costs incurred, which in addition to acquisition costs include additional workload, training resources, storage, incineration of material and potential drug loss in the device.

Strengths and limitations
Two authors independently rated the studies according to the CHEERS checklist. Given the general lack of economic data in the literature, we included all studies that presented costs, even though none of the included studies presented a formal economic evaluation. In the CHEERS analysis, we rated a criterion as 'present' if the study fulfilled any aspect (not necessarily all aspects) of the relevant CHEERS statement (ie, minimal level). Even so, the CHEERS scores were low, and the analysis was conservative.

CONCLUSIONS
This literature review identified a lack of properly conducted economic evaluations of CSTDs, despite their high acquisition costs. As a result, hospitals that are considering implementation of these devices will be unable to make a sound and informed decision.

We advocate for a robust and complete economic evaluation of the use of CSTDs for the preparation and administration of hazardous drugs.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID ID
Cynthia Tanguay http://orcid.org/0000-0003-0969-6051

REFERENCES


